Varicose Vein Treatment with Varithena®


Varithena® lets you easily treat any vein shape and a wide range of sizes*.

  • GSV, AASV, PASV, and visible varicosities
  • Small, medium, and large diameters (including ≥12 mm)
  • Tortuous and recurrent
  • CEAP clinical class 2-6
  • 84% of patients had virtually no symptoms one year after treatment


Benefits of Varithena® 

  • No tumescent anesthesia and a virtually pain-free procedure
  • Cohesive, low-nitrogen microfoam goes where thermal can’t 16 MECHANISM OF ACTION >
  • Data demonstrates efficacy and durability of Varithena® treatment in the GSV EFFICACY >
  • Safety evaluated in 1333 patients in 12 clinical trials SAFETY PROFILE>
  • Support to help you integrate Varithena® into your practice
    • No capital equipment unique to Varithena® required
    • Dedicated CPT codes 36465 and 36466 REIMBURSEMENT >
 

Varithena®: Comprehensive* treatment for GSV system incompetence1,2

Varithena® (polidocanol injectable foam) is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous vein (GSV) system. Varithena® improves the symptoms of superficial venous incompetence and the appearance of visible varicosities. CASE STUDIES >

 

If you would like materials to help tell your patients about Varithena® including patient brochures, posters, press release templates and web announcements, please Contact Us or discuss with your Varithena® Sales representative.

 

Mechanism of Action

 

Are you listed on our  Physician Finder?

                           
Varithena® treats a range of vein anatomies and diameters*
Contact Us
To Become a Varithena® Certified Doctor
Enter security code:
 Security code

Contact Us

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

INDICATIONS

Varithena®  (polidocanol injectable foam) is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous vein (GSV) system above and below the knee. Varithena®  improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.

IMPORTANT SAFETY INFORMATION

The use of Varithena®  is contraindicated in patients with known allergy to polidocanol and those with acute thromboembolic disease.

Severe allergic reactions have been reported following administration of liquid polidocanol, including anaphylactic reactions, some of them fatal. Observe patients for at least 10 minutes following injection and be prepared to treat anaphylaxis appropriately. Intra-arterial injection or extravasation of polidocanol can cause severe necrosis, ischemia or gangrene. Patients with underlying arterial disease may be at increased risk for tissue ischemia. If intra-arterial injection of polidocanol occurs, consult a vascular surgeon immediately.

Varithena®  can cause venous thrombosis. Follow administration instructions closely and monitor for signs of venous thrombosis after treatment. Patients with reduced mobility, history of deep vein thrombosis or pulmonary embolism, or recent (within 3 months) major surgery, prolonged hospitalization, or pregnancy are at increased risk for developing thrombosis. The most common adverse events observed were pain/discomfort in extremity, retained coagulum, injection site hematoma or pain, common femoral vein thrombus extension, superficial thrombophlebitis, and deep vein thrombosis.

Physicians administering Varithena®  must be experienced with venous procedures, possess a detailed working knowledge of the use of the duplex ultrasound in venous disease and be trained in the administration of Varithena® .

See Full Prescribing Information for Varithena®.

Follow Us